Corbus Pharmaceuticals Holdings (CRBP) Price to Sales (2015 - 2021)

Corbus Pharmaceuticals Holdings has reported Price to Sales for 7 years, with the latest figure at 39374.71 in Q3 2021.

• On a quarterly basis, Price to Sales rose 991.53% year-over-year to 39374.71 in Q3 2021; TTM through Jun 2022 was 9738.51, a 279.1% increase from a year earlier, with the FY2021 full-year figure at 2623.48, up 252.53% from the prior year.
• Price to Sales was 39374.71 for Q3 2021 at Corbus Pharmaceuticals Holdings, down from 50286.74 in the prior quarter.
• The five-year high for Price to Sales was 70897.02 in Q2 2020, with the low at 461.92 in Q2 2019.
• Average Price to Sales over 5 years is 16128.39, with a median of 9871.65 recorded in 2017.
• The sharpest annual moves came in 2019 and 2020: Price to Sales tumbled 95.45% in 2019, then surged 15248.18% in 2020.
• Over 5 years, Price to Sales stood at 13528.41 in 2017, then sank by 61.53% to 5204.03 in 2018, then retreated by 20.9% to 4116.32 in 2019, then gained by 8.14% to 4451.5 in 2020, then jumped by 784.53% to 39374.71 in 2021.
• The last three Price to Sales figures came in at 39374.71 (Q3 2021), 50286.74 (Q2 2021), and 11406.57 (Q1 2021), per Business Quant data.